A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone. 

Un simple score para la mortalidad y la insuficiencia cardíaca luego de la terapia borde a borde con MitraClip

However, we did not have a score to predict patient evolution when treated with this strategy.

Researchers analyzed the COAPT study looking to identify the predictors of mortality and hospitalization for cardiac failure. 

The COAPT randomized 614 patients to receiving edge-to-edge plus GDMT vs. GDMT alone.

There were no differences in the populations.

After a two-year followup, Edge-to-edge + GDMT resulted superior, with lower mortality and hospitalization rate for cardiac failure. (44% vs 64.4% P<0.001).

At multivariable analysis, predictors of mortality and cardiac failure were found to be right ventricle systolic pressure, tricuspid failure ≥2+ and kidney failure stage IV.

After adjusting predictors, four clinical and four echocardiographic variables were obtained.  A score was given to each of them. 

Read also: Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons.

The clinical variables were NYHA functional class III-IV (+1), COPD (+1), a history of atrial fibrillation or flutter (+1) and kidney function deterioration, which was divided into stages III (+1) and ≥IV (+3).

The echocardiographic variables were right ventricular systolic pressure >45 mmHg (+3), left ventricle end systolic diameter > 5.5 cm (+2), tricuspid regurgitation ≥2+ (+2), and left ventricular ejection fraction, between 25% and 35% (+1) and <25% (+2).

Patients receiving Edge-to-edge + GDMT were subtracted 3 points (-3).

Scoring went from -3 to 15 points.

Read also: Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair.

Area under the curve of the risk score model was 0.74.

With this risk score, at 2 years, mortality and cardiac failure rates were 34.9%, when the score was between -3-2; 48.9% between 3-4; 63.2% between 5-6; and 83.1% between 7-15.

Conclusion

A simple risk score of clinical, echocardiographic and treatment variables might come in handy for the prognosis of patients with heart failure and severe mitral valve regurgitation. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Prediction of Death or HF Hospitalization in Patients With Severe FMR. The COAPT Risk Score.

Reference: Neeraj Shah, et al. J Am Coll Cardiol Intv 2022;15:1893–1905.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...